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Abstract 
Background: To determine the types, 
characteristics, treatment and outcome of cardiac 
tachyarrhythmias. 
Methods: In this  cross sectional study, 78  patients 
with symptomatic cardiac tachyarrhythmias were 
assessed for age, sex, associated cardiovascular risk 
factors and treatment options. Monitoring was done 
for cardiac tachyarrhythmias at presentation or 
during hospital stay with documentation of the 
arrhythmias from the cardiac monitor memory and/or 
instant 12-lead ECG.  
Results: Mean age was 57.1 years. Male to female 
ratio was 1.38:1. Major cardiovascular risk factors 
were encountered in 58% of the patients. 
Tachyarrhythmias occurred in 42% patients without 
any associated risk factor. Only 28% of patients with 
ventricular tachycardia (VT) were managed with 
drugs alone. Defibrillation was required in all the 
patients with ventricular fibrillation (VF). All the 
patients with pulseless VT (33%) were defibrillated 
but the stable VT with pulse were treated with 
antiarrhythmic drug (28%) and unstable VT with 
pulse (72%) received synchronized cardioversion. 
The patients with SVT were treated with drugs alone 
(33%), drugs followed by cardioversion (45%) and 
cardioversion alone (22%). Inj. Verapamil 5 mg 
(either alone or prior to cardioversion) was given to 
78% patients with SVT as compared to cardioversion 
alone (22%). Verapamil was given as monotherapy 
(43%), verapamil + beta blockers (29%), verapamil + 
amiodarone (21%), and combination of all three 
antiarrhythmic drugs to 7% patients. 
Pharmacological therapy was also offered to patients 
who presented with stable AF with fast ventricular 
rate, which included beta blockers 50% (4/8), 
amiodarone to 12.5% (1/8), digoxin to 25% (2/8), and 
combination of beta blockers and amiodarone 12.5% 
(1/8) patients.  
Conclusion: Wide complex tachyarrhythmias like 
ventricular tachyarrhytmias and ventricular 
fibrillation are common. Electrical therapy is a 
preferred choice to treat any form of 
tachyarrhythmia. Atrial fibrillation is the most 
treatment-resistant tachyarrhythmia.  
Key Words: Tachyarrhythmia, antiarrhythmic 
drugs. 
 
Introduction 
     Cardiac tachyarrhythmias are very important cause 
of preventable death worldwide. Arrhythmias affect 
over 7 million people in England and approximately 
14.4 million people in USA. The vast majority of these 
tachyarrhythmias are associated with underlying 
cardiovascular risk factors.1,2 Wide complex 
tachyarrhythmias (WCT), VT and VF, occur in up to 
20% of patients with acute coronary syndromes. In 
hospitalized patients with acute coronary syndromes, 
the most common WCT is primary VF, which occurs 
in 3-5% of patients within the first few hours following 
onset of infarction. Cardiac arrhythmias, especially VF, 
is the most common cause of out-of-hospital as well as 
in-hospital cardiac arrest and sudden death,. It is 
estimated that serious ventricular tachyarrhythmias 
are responsible for death in nearly 50% of patients 
with coronary artery disease.  High quality 
resuscitation for in-hospital cardiac arrest has 
improved the survival to a great extent. Inadequate 
management of cardiac arrhythmia may lead to many 
complications like TIA, stroke and thromboembolism 
phenomenon.3-11  
    Many tachyarrhythmias are stable and the only 
complaint is palpitation. Some of the tachyarrhythmias 
are really fast and fatal if they are associated with poor 
signs of perfusion. All such unstable tachyarrhythmias 
are generally treated with electrical therapy, while all 
those tachyarrhythmias with adequate perfusion 
(stable) are best managed pharmacologically. 
Tachyarrhythmias of ventricular origin e.g. VT and VF 
are more dangerous and can lead to sudden cardiac 
death if not treated on time. Tachyarrhythmias of 
atrial origin e.g. AF/Flutter can predispose the patient 
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to potentially life threatening thrombo-embolism 
phenomenon, including stroke. Hands-on training in 
Advanced Cardiac Life Support (ACLS) programmes 
has improved the skills and practical approach of 
many healthcare providers. More and more hospitals 
are involved in such training activities.12-15 
     Arrhythmias can cause considerable anxiety if a 
person becomes aware of them, which subsequently 
may lead to more serious arrhythmias. Stress related 
brain activity influences cardiac electrophysiology and 
is linked to arrhythmias via the autonomic nervous 
system, through an accelerated catecholamine release. 
About 15% individuals develop post traumatic stress 
disorder (PTSD) after a heart attack. PTSD causes 
emotional and psychological distress and slows 
recovery. Preliminary findings suggest that various 
psychotherapeutic modalities may be effective. Such 
studies also provide an avenue through which the 
physical and psychological mechanisms involved in 
coronary heart disease and their interactions may be 
clarified.16-20 
Patients and Methods 
      This study was carried out in adult cardiology 
department at Sialkot Medical Complex Sialkot, 
Pakistan from June 2009 to August 2010. Consecutive 
patients (n=78) with symptomatic cardiac 
tachyarrhythmias were assessed for age, sex, 
associated cardiovascular risk factors, and treatment 
options including drugs and/or electrical therapy. All 
the treatments were provided according to AHA/ECC 
2005 CPR guidelines.15 Monitoring was done for 
cardiac tachyarrhythmias at presentation or during 
hospital stay with documentation of the arrhythmias 
from the cardiac monitor memory and/or instant 12-
lead ECG.All the patients with Ventricular Fibrillation 
(VF), Ventricular Tachycardia (VT), Supraventricular 
Tachycardia (SVT), and Atrial Fibrillation (AF) were 
included in the study. Patients less than 18 years, 
premature ectopic and cardiac arrest with non-shock 
able rhythm (PEA/Asystole) were excluded from the 
study. All the patients were admitted to monitored 
bed in the cardiology department and observed for 
continuous ECG monitoring 
Results 
     Mean age for cardiac tacharrhythmia was 57.1 
years. The distribution of tachyarrhythmias in male 
and female was 58% and 42%, respectively. One or  
more risk factor were encountered in 58%(Table 1). 
Only 28% patients with VT were managed with drugs  
alone. AF was more responsive to pharmacological  
therapy as compared to VT. Defibrillation was 
required  in all patients with VF. 
 
Table 1:Types and Distribution of  
Tachyarrhthmias. 
 
Type of 
tachyarrhythmias 
Wide complex 
tachycardia 
Narrow complex 
tachycardia 
VF VT 
with 
pulse 
Pulseles
s VT 
SVT AF 
Gender 
Male= 45 (58%) 12(26%) 13(28%) 6 (13%)  7(15%) 7(15%) 
Female=33 (42%) 9 (27%) 5 (15%) 3 (9%)  11(33%) 5(15%) 
Cardiovascular Risk factors (DM, HTN, previous CAD, smoking, 
hyperlipidemia) 
Yes,n=45 (58%) 15(31%) 12(26%) 5 (11%)  6 (13%) 9(19%) 
No, n=33 (42%) 9 (26%) 5 (14%) 6 (17%)  12(34%) 3 (9%) 
  
Wide complex tachyarrhythmias (n= 48) were either 
VF (44%) or VT (56%). All patients with VF were 
subjected to defibrillation. The patients with VT were 
divided into two groups i.e., pulseless VT (33%) and 
VT with pulse (67%). All the patients with Pulseless 
VT were defibrillated but the Stable VT with pulse 
were treated with antiarrhythmic drug amiodarone 
(28%) and unstable VT with pulse (72%) received 
synchronized cardioversion. All the patients in the 
group of VT with pulse, whether stable or unstable 
had received Inj. Amiodarone150 mg over 10 minutes 
(Table 2).  
 
Table 2: Treatment options for all tachyarrhythmias 
Type of 
tachyarrhythmias 
Wide Complex Tachycardia, n= 48 Narrow Complex Tachycardia, n= 30 
VF (n= 21) Pulseless VT( n= 9) VT with pulse, (n=18) SVT(n= 18)          AF(n= 12) 
Therapy 
Drugs alone - - 5 (28%) 6 (33%) 8 (67%) 
Drugs + Cardioversion - - - 8 (45%) - 
Cardioversion alone - - 13 (72%) 4 (22%) 4 (33%) 
Defibrillation 21 (100%) 9 (100%) - - - 
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Table 3: Treatment modalities of 
tachyarrhythmias 
Tachyarrhythmias Drugs 
alone 
Electrical therapy 
(alone or combined 
with drugs) 
Narrow Complex 
(n=30) 
14 (47%) 16 (53%) 
Wide Complex (n=48) 5 (10%) 43 (90%) 
Total (n= 78) 19 (24%) 59 (76%) 
 
Table 4: Drugs used to treat narrow complex 
tachyarrhythmias. 
Drug treatment of SVT (n=14) 
Verapamil 
alone 
Verapamil + 
B-blockers 
Verapamil + 
Amiodarone 
Combination 
of drugs 
N= 6 (43%) N= 4 (29%) N= 3 (21%) N= 1 (7%) 
Rate-controlling drugs for AF (n=8) 
B-blockers Amiodarone Digoxin B-blockers + 
Amiodarone 
4 (50%) 1 (12.5%) N=2 (25%) 1 (12.5%) 
 
     Inj. Verapamil 5 mg IV (either alone or prior to 
cardioversion) was given to 78% patients with SVT as 
compared to cardioversion alone (22%). Verapamil 
was given as monotherapy (43%), verapamil + beta 
blockers (29%), verapamil + amiodarone (21%), and 
combination of all three antiarrhythmic drugs to 7% 
patients. Pharmacological therapy was also offered to 
patients presented with stable AF with fast ventricular 
rate (n=8/12) which includes beta blockers 50% (4/8), 
amiodarone to 12.5% (1/8), digoxin to 25% (2/8), and 
combination of beta blockers and amiodarone 12.5% 
(1/8) patients (Table 4).  
 
Discussion 
     In present study men were found to be more prone 
than women to tachyarrhythmias (58% vs. 42%). 
Tachyarrhythmias are common hospital presentation 
in middle age group as the incidence of coronary 
artery disease is exceedingly increased with advancing 
age. Men (58%) are at greater risk of sudden cardiac 
death. Patients with cardiovascular risk factor were 
more prone to life threatening WCT (58%). 
Tachyarrhythmias also occurred in 42% patients 
without any associated CV risk factor. VT was the 
most common rhythm observed in patients with or 
without underlying CV risk factors but SVT was seen 
in 34% of NCT without any associated CV risk factor. 
This is also consistent with the study conducted by 
Budhwar N and et al.21 
     It is important to note that the conversion rate of 
tachyarrhythmias to normal sinus rhythm (NSR) was 
44% as compared to other reperfusion rhythms (40%). 
Maximum conversion rate to NSR was seen in SVT 
(72%), followed by VT with pulse (33%), VF (33%), and 
pulseless VT (22%) respectively. These findings also 
showed that 84% of the tachyarrhythmias responded 
to one or other form of treatment (antiarrhythmic 
drugs and/or electrical therapy). This reflects that 
many episodes of sudden cardiac death in hospital 
settings can be avoided by timely identification and 
treatment of tachyarrhythmia. The small percentage 
(9%) succumbs to death due to unsuccessful 
resuscitation and it was noticeable that all the failed 
resuscitations fall in WCT group.  But all the treatment 
resistant tachyarrhhmias (7%) were NCT group (AF 
followed by SVT). AF was found to be the most 
frequent treatment-resistant tachyarrhythmia and 
more resistant to treatment in female than male (F:M – 
9%: 4%).Of all the cardiac arrhythmias seen in clinical 
practice, atrial fibrillation (AF) and ventricular 
tachycardia/fibrillation (VT/VF) are among the 
leading causes of morbidity and mortality in the 
developed world. AF is the most common sustained 
arrhythmia and is associated with an increased risk of 
stroke, heart failure, dementia, and death. 22 
      In our study, out of 30 patients with NCT, 60% 
were SVT and 40% were AF. These figures are very 
near to the other national and international studies 
where again SVT is the most common arrythmia.The 
patients with SVT were treated with drugs alone 
(33%), drugs followed by cardioversion (45%) and 
cardioversion alone (22%). Intravenous adenosine was 
used for all patients with stable SVT. Most of the 
centers around the world are using adenosine as first 
line treatment. 22 
   Although adenosine is the antiarrhythmic drug of 
choice to treat SVT in all ages but the drug used at our 
center was verapamil 5 mg IV (because of lack of 
availability of adenosine in this part of world). It 
should be appreciated that the conversion rate with 
verapamil (a calcium channel blocker) was 72%. The 
rate-controlling agents used for AF were b-blockers 
metoprolol, amiodarone, digoxin and combination of 
beta blocker + amiodarone. Beta blockers were used in 
50% of the patients having AF with fast ventricular 
rate. Digoxin was used in patients with AF (25%) 
complicated by congestive cardiac failure (CCF). 23 
     ST/T changes consistent with acute coronary 
syndrome (ACS) were detected in 22% patients with 
tachyarrhythmias in post-therapy period and all of 
them (100%) were seen in patient treated for WCT. 
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This confirms the strong association between WCT 
and acute coronary syndromes and signifies the fact 
that approximately 1/4 of the patients with ACS-
specific ST/T changes are expected to suffer WCT and 
vice versa and they are at great risk of cardiac arrest 
and sudden death. 24 
   
Conclusion 
1.Life-threatening tachyarrhythmias can be managed 
effectively by following the proper  resuscitation 
guidelines. 
2. Healthcare professional  should be exposed to some 
sort of resuscitation training.  
3.Majority of tachyarrhythmias are treatment-
responsive if identified and managed appropriately. 
4.Cardioversion is most effective therapy for VT with 
pulse and SVT irrespective of the clinical picture of the 
patient being stable or unstable.  
5.Defibrillation remains the therapy of choice for 
pulseless VT and VF.  
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